November 05, 2024

Arlington, Va. —  The Medical Imaging & Technology Alliance (MITA), a division of the National Electrical Manufacturers Association (NEMA), applauds the Centers for Medicare & Medicaid Services (CMS) for finalizing Medicare payment changes for diagnostic radiopharmaceuticals in its Hospital Outpatient Prospective Payment System (OPPS) rule.

In the final 2025 OPPS Rule, diagnostic radiopharmaceuticals with a per-day cost above $630 will now be paid separately by CMS for traditional Medicare Fee for Service patients in OPPS after pass-through payment status ends.

According to Sue Bunning, MITA’s Managing Director of Positron Emission Tomography, “MITA applauds the CMS decision that will increase access to diagnostic radiopharmaceutical drugs that are essential to provide patients with accurate diagnoses and access to a number of therapies. MITA appreciates the time and attention given by CMS to this issue, and we look forward to working with the agency on its implementation. This decision has the ability to change lives.” 

MITA is the leading organization and collective voice of radiopharmaceutical manufacturers, innovators, and product developers. MITA applauds the united voices of over 125 organizations of patients, physicians, hospitals, drug innovators and manufacturers who supported separate payment for diagnostic radiopharmaceuticals. Additionally, we thank the Members of Congress who worked this year to advance the Facilitating Innovative Nuclear Diagnostics (FIND) Act.